# Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants

> **NCT02824315** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AL-335
- **DRUG:** Odalasvir (ODV)
- **DRUG:** Simeprevir (SMV)

## Key facts

- **NCT ID:** NCT02824315
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824315, "Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02824315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*